Eton Pharmaceuticals, Inc. (ETON)
- Previous Close
8.00 - Open
8.00 - Bid 5.91 x 200
- Ask 9.85 x 200
- Day's Range
7.63 - 8.19 - 52 Week Range
3.03 - 8.20 - Volume
233,660 - Avg. Volume
128,817 - Market Cap (intraday)
211.598M - Beta (5Y Monthly) 1.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.26 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.50
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
www.etonpharma.com30
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ETON
View MorePerformance Overview: ETON
Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETON
View MoreValuation Measures
Market Cap
211.34M
Enterprise Value
198.45M
Trailing P/E
113.67
Forward P/E
23.36
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.71
Price/Book (mrq)
15.70
Enterprise Value/Revenue
6.32
Enterprise Value/EBITDA
51.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.31%
Return on Assets (ttm)
-12.50%
Return on Equity (ttm)
-44.30%
Revenue (ttm)
31.38M
Net Income Avi to Common (ttm)
-6.69M
Diluted EPS (ttm)
-0.26
Balance Sheet and Cash Flow
Total Cash (mrq)
17.69M
Total Debt/Equity (mrq)
36.23%
Levered Free Cash Flow (ttm)
-380.25k